Tezspire Demonstrates Positive Phase III Results in Eosinophilic Esophagitis Across Both Co-primary and All Key Secondary Endpoints
August 28, 2026
August 28, 2026
WILMINGTON, Delaware, Aug. 28 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52
Efficacy in a third epithelial-driven inflammatory disease supports . . .
* * *
TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52
Efficacy in a third epithelial-driven inflammatory disease supports . . .